Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933

Cancer

Volumn 121, Issue 3, 2015, Pages 432-440

  Lee, Sylvia M ^a   Moon, James ^b   Redman, Bruce G ^c   Chidiac, Tarek ^d   Flaherty, Lawrence E ^e   Zha, Yuanyuan ^f   Othus, Megan ^b   Ribas, Antoni ^g   Sondak, Vernon K ^h   Gajewski, Thomas F ^f   Margolin, Kim A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d Mid Ohio Oncology Hematology   (United States)

^e WAYNE STATE UNIVERSITY   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

^g UCLA MEDICAL CENTER   (United States)

^h H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Gamma secretase inhibitor; Metastatic melanoma; Notch; RO4929097

Indexed keywords

ALPHA INTERFERON; AMINOTRANSFERASE; DENILEUKIN DIFTITOX; INTERLEUKIN 2; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; NOTCH RECEPTOR; SARGRAMOSTIM; 2,2-DIMETHYL-N-(6-OXO-6,7-DIHYDRO-5H-DIBENZO(B,D)AZEPIN-7-YL)-N'-(2,2,3,3,3-PENTAFLUOROPROPYL)MALONAMIDE; BENZAZEPINE DERIVATIVE; ENZYME INHIBITOR; SECRETASE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUTANEOUS MELANOMA; CYTOKINE PRODUCTION; DIARRHEA; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPONATREMIA; HYPOPHOSPHATEMIA; LIMB PAIN; LYMPHOCYTE COUNT; MALE; METASTATIC MELANOMA; NAUSEA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; SURVIVAL RATE; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; VOMITING; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; IMMUNOLOGY; MELANOMA; METABOLISM; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMYLOID PRECURSOR PROTEIN SECRETASES; BENZAZEPINES; DISEASE-FREE SURVIVAL; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTORS, NOTCH; SURVIVAL RATE; T-LYMPHOCYTES;

EID: 84921498604     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29055     Document Type: Article

References (27)

1. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999;284:770-776.
2. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306:269-271.
3. Leong KG, Karsan A. Recent insights into the role of Notch signaling in tumorigenesis. Blood. 2006;107:2223-2233.
4. Li G, Schaider H, Satyamoorthy K, Hanakawa Y, Hashimoto K, Herlyn M. Downregulation of E-cadherin and desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene. 2001;20:8125-8135.
5. Lehmann JM, Holzmann B, Breitbart EW, Schmiegelow P, Riethmuller G, Johnson JP. Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000. Cancer Res. 1987;47:841-845.
6. Liu ZJ, Xiao M, Balint K, et al. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res. 2006;66:4182-4190.
7. Bedogni B, Warneke JA, Nickoloff BJ, Giaccia AJ, Powell MB. Notch1 is an effector of Akt and hypoxia in melanoma development. J Clin Invest. 2008;118:3660-3670.
8. Pinnix CC, Lee JT, Liu ZJ, et al. Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Res. 2009;69:5312-5320.
9. Massi D, Tarantini F, Franchi A, et al. Evidence for differential expression of Notch receptors and their ligands in melanocytic nevi and cutaneous malignant melanoma. Mod Pathol. 2006;19:246-254.
10. Tsukumo S, Yasutomo K. Notch governing mature T cell differentiation. J Immunol. 2004;173:7109-7113.
11. Kuijk LM, Verstege MI, Rekers NV, et al. Notch controls generation and function of human effector CD81 T cells. Blood. 2013;121:2638-2646.
12. Bohler T, Nolting J, Kamar N, et al. Validation of immunological biomarkers for the pharmacodynamic monitoring of immunosuppressive drugs in humans. Ther Drug Monit. 2007;29:77-86.
13. Tolcher AW, Messersmith WA, Mikulski SM, et al. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol. 2012;30:2348-2353.
14. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26:527-534.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
16. Brookmeyer R, Crowley J. A k-sample median test for censored data. J Am Stat Assoc. 1982;77:433-440.
17. Palaga T, Miele L, Golde TE, Osborne BA. TCR-mediated Notch signaling regulates proliferation and IFN-gamma production in peripheral T cells. J Immunol. 2003;171:3019-3024.
18. Radtke F, Wilson A, Stark G, et al. Deficient T cell fate specification in mice with an induced inactivation of Notch1. Immunity. 1999;10:547-558.
19. Radtke F, Wilson A, Mancini SJ, MacDonald HR. Notch regulation of lymphocyte development and function. Nat Immunol. 2004;5:247-253.
20. Tran IT, Sandy AR, Carulli AJ, et al. Blockade of individual Notch ligands and receptors controls graft-versus-host disease. J Clin Invest. 2013;123:1590-1604.
21. Sandy AR, Chung J, Toubai T, et al. T cell-specific Notch inhibition blocks graft-versus-host disease by inducing a hyporesponsive program in alloreactive CD41 and CD81 T cells. J Immunol. 2013;190:5818-5828.
22. Strosberg JR, Yeatman T, Weber J, et al. A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer. 2012;48:997-1003.
23. Paganin M, Ferrando A. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev. 2011;25:83-90.
24. Milano J, McKay J, Dagenais C, et al. Modulation of Notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci. 2004;82:341-358.
25. Wong GT, Manfra D, Poulet FM, et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem. 2004;279:12876-12882.
26. van Es JH, van Gijn ME, Riccio O, et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature. 2005;435:959-963.
27. Jenkins DW, Ross S, Veldman-Jones M, et al. MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo. Mol Cancer Ther. 2012;11:1650-1660.